Given that a number of other sphingolipid catabolic enzymes have been implicated in Lewy body disease more broadly, including SMPD1, GALC and ARSA, future studies may wish to determine whether targeting the function of their protein products, or the prosaposins that activate many of these enzymes, is a useful therapeutic strategy in DLB. The gene discussed is GALC; the disease is Lewy body dementia.